162 related articles for article (PubMed ID: 10414943)
1. Reversal of multidrug resistance in hematological malignancies.
Vossebeld PJ; Sonneveld P
Blood Rev; 1999 Jun; 13(2):67-78. PubMed ID: 10414943
[No Abstract] [Full Text] [Related]
2. Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies.
Sonneveld P
Eur J Cancer; 1996 Jun; 32A(6):1062-9. PubMed ID: 8763348
[No Abstract] [Full Text] [Related]
3. MDR1/P-glycoprotein in haematological neoplasms.
Marie JP; Zhou DC; Gurbuxani S; Legrand O; Zittoun R
Eur J Cancer; 1996 Jun; 32A(6):1034-8. PubMed ID: 8763345
[No Abstract] [Full Text] [Related]
4. Multidrug resistance in haematological malignancies.
Sonneveld P
J Intern Med; 2000 May; 247(5):521-34. PubMed ID: 10809991
[TBL] [Abstract][Full Text] [Related]
5. Is p-glycoprotein a potential target for reversing clinical drug resistance?
Dalton WS
Curr Opin Oncol; 1994 Nov; 6(6):595-600. PubMed ID: 7827171
[TBL] [Abstract][Full Text] [Related]
6. Novel mechanisms of drug resistance in leukemia.
Ross DD
Leukemia; 2000 Mar; 14(3):467-73. PubMed ID: 10720143
[TBL] [Abstract][Full Text] [Related]
7. Both P-gp and MRP contribute to drug resistance in AML.
Legrand O; Simonin G; Zittoun R; Marie JP
Leukemia; 1998 Aug; 12(8):1327-8. PubMed ID: 9697893
[No Abstract] [Full Text] [Related]
8. Multidrug resistance transporters and modulation.
Tan B; Piwnica-Worms D; Ratner L
Curr Opin Oncol; 2000 Sep; 12(5):450-8. PubMed ID: 10975553
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
[TBL] [Abstract][Full Text] [Related]
10. Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphoma.
Dalton WS
Hematol Oncol Clin North Am; 1997 Oct; 11(5):975-86. PubMed ID: 9336726
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation.
Shustik C; Dalton W; Gros P
Mol Aspects Med; 1995; 16(1):1-78. PubMed ID: 7783568
[No Abstract] [Full Text] [Related]
12. The phenomenon of multidrug resistance in non-Hodgkin's lymphoma.
Miller TP; Chase EM; Dalton WS; Grogan TM
Cancer Treat Res; 1996; 85():107-17. PubMed ID: 9043778
[No Abstract] [Full Text] [Related]
13. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
[TBL] [Abstract][Full Text] [Related]
14. The role of P-glycoprotein in drug resistance in multiple myeloma.
Abraham J; Salama NN; Azab AK
Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978
[TBL] [Abstract][Full Text] [Related]
15. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells.
den Ouden D; van den Heuvel M; Schoester M; van Rens G; Sonneveld P
Leukemia; 1996 Dec; 10(12):1930-6. PubMed ID: 8946933
[TBL] [Abstract][Full Text] [Related]
16. A diagnostic tool for monitoring multidrug resistance expression in human tumor tissues.
Schwarzenbach H
Anal Biochem; 2002 Sep; 308(1):26-33. PubMed ID: 12234460
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
[TBL] [Abstract][Full Text] [Related]
18. Modulation of multidrug resistance in multiple myeloma.
Sonneveld P
Baillieres Clin Haematol; 1995 Dec; 8(4):831-44. PubMed ID: 8845575
[TBL] [Abstract][Full Text] [Related]
19. A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples.
Illmer T; Schaich M; Oelschlägel U; Nowak R; Renner U; Ziegs B; Subat S; Neubauer A; Ehninger G
Leuk Res; 1999 Jul; 23(7):653-63. PubMed ID: 10400187
[TBL] [Abstract][Full Text] [Related]
20. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
Broxterman HJ; Sonneveld P; Pieters R; Lankelma J; Eekman CA; Loonen AH; Schoester M; Ossenkoppele GJ; Löwenberg B; Pinedo HM; Schuurhuis GJ
Leukemia; 1999 Feb; 13(2):258-65. PubMed ID: 10025900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]